Hikari Power’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Hikari Power’s Portfolio TARO Stock Details TARO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,560	Closed	-$277K	–	145
2019 Q1	$277K	Hold	2,560	–	–	0.03%	102
2018 Q4	$217K	Hold	2,560	–	–	0.02%	109
2018 Q3	$252K	Hold	2,560	–	–	0.03%	112
2018 Q2	$296K	Buy	+2,560	New	+$281K	0.03%	89

Other funds holding TARO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CAM

Claret Asset Management Montreal, Quebec, Canada $837M AUM 25.51% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Hikari Power's TARO Position: Q2 2019 in Review

Hikari Power sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q2 2019, closing a stake of 2,560 shares — an estimated $277K sold.

Hikari Power first reported a position in TARO in Q2 2018 and held it in 4 quarters. The position peaked at $296K in Q2 2018. 105 funds tracked by Wall St. Rank hold TARO as of Q2 2019.

Hikari Power reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q2 2019 after selling out during the quarter.
Hikari Power sold 2,560 Taro Pharmaceutical Industries Ltd. shares in Q2 2019, an estimated $277K.
Hikari Power first reported a position in Taro Pharmaceutical Industries Ltd. in Q2 2018 and held it in 4 quarters.
Hikari Power's Taro Pharmaceutical Industries Ltd. position peaked at $296K in Q2 2018.
105 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q2 2019.

Based on Hikari Power's 13F filing for Q2 2019, filed 8 Aug 2019.